Related Experiment Video
Updated: Aug 13, 2026

A Multimodal Imaging- and Stimulation-based Method of Evaluating Connectivity-related Brain Excitability in Patients with Epilepsy
Published on: November 13, 2016
[Magnetic resonance imaging of the brain in phenylketonuria]
Mina Izumi1, Hirotaka Yamazaki, Hiroki Nakabayashi
1Department of Pediatrics, Nihon University Surugadai Hospital, Tokyo.
Insights
High blood phenylalanine (Phe) levels in phenylketonuria (PKU) and hyperphenylalaninemia (HPA) correlate with brain white matter abnormalities on MRI scans. Long-term dietary control is a stronger predictor than short-term Phe levels.
Area of Science:
- Neurology
- Radiology
- Metabolic Disorders
Context:
- Phenylketonuria (PKU) and hyperphenylalaninemia (HPA) are genetic metabolic disorders.
- Early detection and treatment are crucial for managing PKU and HPA.
- Brain imaging, particularly MRI, can reveal abnormalities associated with these conditions.
Purpose:
- To investigate the correlation between brain MRI findings and blood phenylalanine levels in patients with PKU and HPA.
- To assess the influence of different blood phenylalanine measurement periods (lifetime average, 6 months, 12 months) on MRI results.
- To compare MRI findings in early-treated versus late-detected PKU patients.
Summary:
- Brain MRI abnormalities, specifically white matter hyperintensities on T2-weighted and FLAIR sequences, were observed in patients with higher blood phenylalanine levels (9-12 mg/dl and >12 mg/dl).
- MRI findings correlated more strongly with long-term dietary control (lifetime average phenylalanine) than with shorter-term measurements (6 or 12 months prior to MRI).
- No significant MRI abnormalities were found in patients with phenylalanine levels below 5 mg/dl.
Impact:
- This study highlights the utility of MRI in assessing the neurological impact of PKU and HPA.
- Findings suggest that sustained high phenylalanine levels, even in treated individuals, can lead to detectable brain changes.
- Further research is needed to clarify the clinical significance of these MRI abnormalities and their long-term consequences.
Abstract:
To investigate the correlation between the abnormalities of magnetic resonance imaging (MRI) of the brain and blood phenylalanine (Phe) levels in phenylketonuria (PKU) and hyperphenylalaninemia (HPA), we reviewed MRIs from 16 patients with early treated PKU and HPA. Their ages ranged from 4-24 years and were found by mass screening and treated from early infancy, and 5 patients with late detected PKU who were aged 24-33 years. The former patients had no remarkable neurological signs or symptoms. One patient of the latter had severe mental retardation and 3 patients had mild to border mental retardation. Axial T1-weighted and T2-weighted spin echo sequences, fluid attenuated inversion recovery MR sequences (FLAIR) through the brain were performed. The scans were graded according to the extent of increased signal intensity of white matter on T2-weighted and FLAIR sequences. To investigate the influence of plasma Phe levels, three approaches were used. Firstly an average of all yearly serial blood Phe concentration was calculated for each patient, then Phe was determined for a period of 6 months and 12 months prior to MRI, and also for their lifetime up to their age at the time this study began. These average blood Phe levels were classified into four categories: group A:Phe level below 5 mg/dl, group B:5-8 mg/dl, group C:9-12 mg/dl, group D:above 12 mg/dl. MRI findings were not significant in group A. Remarkable high signals of white matter were obtained in group C and D, except for one patient in group D whose MRI finding was normal. MRI findings correlated to long-term dietary control stronger than those of 6 months prior to MRI. The clinical significance of MRI abnormalities is still unclear, and further study is required to clarify the relationship of the MRI findings and clinical conditions.
Related Concept Videos
Magnetic Resonance Imaging
Imaging Studies IV: Magnetic Resonance Imaging
Brain Imaging
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic Stimulation (TMS).
